A personal critique: evidence-based medicine, methodology, and ethics of randomised clinical trials.
Evidence-based medicine may influence our approach to clinical trials. When preparing a systematic review, the quality of individual trials is of far greater importance than their individual results. Unbiased randomisation, attention to the treatment protocol and to the rules of good clinical practice and honest evaluation of experience are essential; less important is the power of an individual trial and the statistically significant difference between the treatment arms. The recruitment period should be short, followed by timely publication of a report. Since systematic reviews and meta-analyses include and quote all available information, clinical researchers and editors should be less influenced by publication bias. These changes in methodology open clinical trials to new innovative ideas difficult to test in large multi-institutional trials, rend clinical investigators less dependent on commercial sponsors and might bring more patients into clinical research.
Zwitter
M
M
Institute of Oncology, Zaloska 2, 1000, Ljubljana, Slovenia. mzwitter@onko-si
D017322:Clinical Trials, Phase II as Topic / Q000592:standards; D019317:Evidence-Based Medicine; D006801:Humans; D015337:Multicenter Studies as Topic / Q000592:standards; D018579:Patient Selection; D011643:Publishing / Q000592:standards; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D016896:Treatment Outcome